Should TIA Patients with Resolved Symptoms and Negative MRI Be Sent Home on Aspirin?
No, patients with TIA should NOT simply be sent home on aspirin alone—they require risk stratification and, if high-risk, should receive dual antiplatelet therapy (aspirin plus clopidogrel) for 21-30 days before transitioning to monotherapy. 1
Risk Stratification is Critical
The key decision point is determining whether this is a high-risk TIA. According to the most recent Canadian guidelines, high-risk features include 1:
- ABCD2 score ≥4 (or POINT trial criteria)
- Unilateral weakness (face, arm, or leg)
- Speech disturbance lasting >5 minutes
- Recurrent events
- Significant ipsilateral large artery disease (carotid stenosis, intracranial stenosis)
Treatment Algorithm
For High-Risk TIA (ABCD2 ≥4 or features above):
Dual antiplatelet therapy should be initiated immediately 1:
- Loading doses: Clopidogrel 300-600 mg + Aspirin 160 mg
- Maintenance: Clopidogrel 75 mg + Aspirin 81-325 mg daily for 21-30 days
- Then switch to single antiplatelet therapy (aspirin or clopidogrel alone) indefinitely
This approach reduces stroke risk from 7.8% to 5.2% (hazard ratio 0.66) 2. The 2018 Canadian guidelines specifically recommend starting dual therapy before discharge from the ED and within 24 hours of symptom onset, ideally within 12 hours 1.
For Lower-Risk TIA:
If the patient does not meet high-risk criteria, aspirin monotherapy is appropriate 3:
- Loading dose: Aspirin 160-325 mg immediately
- Maintenance: Aspirin 81-325 mg daily indefinitely
Alternative options include aspirin-dipyridamole combination or clopidogrel monotherapy 3, 4.
Critical Caveats
Do not discharge on aspirin alone if:
- The patient has cardioembolic TIA (atrial fibrillation, valvular disease)—these patients need anticoagulation, not antiplatelet therapy 3
- There is significant carotid stenosis (70-99%)—urgent carotid endarterectomy may be needed within 2 weeks, and the surgeon should guide antiplatelet selection 1
Ensure specialist follow-up within 24 hours of symptom onset, preferably in a dedicated TIA clinic 5.
Why This Matters for Outcomes
The evidence is clear that early recurrent stroke risk is highest in the first few days after TIA 6, 7. The European Stroke Organisation guidelines emphasize that 7.5-17.4% of TIA patients will have a stroke within 3 months if not properly managed 2.
Dual antiplatelet therapy prevents 15 ischemic strokes per 1000 patients treated over 90 days, though it causes 5 major hemorrhages per 1000 patients 1. This favorable risk-benefit ratio justifies the short-term bleeding risk in high-risk patients.
Common Pitfalls to Avoid
- Don't rely on ABCD2 score alone—patients with scores ≤3 can still be at significant stroke risk 5
- Don't continue dual antiplatelet therapy beyond 21-30 days—hemorrhage risk outweighs benefit after this period 8, 9
- Don't forget to counsel patients that dual therapy is temporary and they must switch to monotherapy after 21-30 days 1
- Don't miss atrial fibrillation—these patients need anticoagulation, not antiplatelets 3
The negative MRI does not change management—TIA is a clinical diagnosis, and tissue-based definitions should not delay treatment 7.